Expert Interview
Discussing the FDA Approval of Amicus Therapeutics' Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) combo therapy for treating Pompe Disease.
Ticker(s): FOLDInstitution: McMaster University
- Professor of Pediatrics and Medicine, Director of Neuromuscular and Neurometabolic Clinic at McMaster University Medical Center.
- Manages 21 patients with Pompe Disease and served as a PI for the PROPELL study
- Research focuses on mitochondrial diseases, muscle disorders, and other neurometabolic disorders, and has been involved in clinical trials in in Duchenne muscular dystrophy, Friedreich's ataxia and Pompe disease
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
